1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Vicapsys Life Sciences, Inc.

Vicapsys Life Sciences, Inc.

VICP
Vicapsys Life Sciences, Inc.US flagOther OTC
1.46
USD
- -
- -
47.26MMarket Cap
2008 Y
2009 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
19.99
22.45
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-7.16
-4.82
-0.12
-0.04
-0.01
-0.03
-0.03
-0.04
Free Cash Flow per Basic Share
-5.03
-4.24
-0.09
-0.02
-0.03
-0.01
-0.01
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-12.35
-16.93
-1.15
-0.79
-0.8
-0.49
-0.47
-0.51
Tangible Book Value per Share
-4.36
-7.88
-0.01
-0.05
-0.03
-0.03
-0.06
-0.08
Basic Weighted Avg Shares
- -
- -
11
17
18
31
35
34
Sales/Revenue/Turnover
7
8
- -
- -
- -
- -
- -
- -
Operating Margin (%)
-34.69
-17.39
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-2
-2
-1
-1
- -
-1
-1
-1
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-35.83
-21.45
- -
- -
- -
- -
- -
- -
Working Capital
-2
-2
- -
-1
- -
-1
-2
-3
LT Debt
- -
1
- -
- -
- -
- -
- -
- -
Total Equity
-1
-3
- -
- -
- -
-1
-2
-3
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
- -
- -
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
32
32
32
Market Capitalization
17
59
59

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
2
2
3
Payables & Accruals
2
2
2
ST Debt
- -
- -
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
70.35%
102.85%
Free Cash Flow
- -
-1.81%
75.29%
Net Income, GAAP
- -
41.09%
20.04%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
-0.01
-0.01
- -
- -
-0.03
2023
-0.01
- -
-0.01
- -
-0.03
2024
-0.01
-0.01
-0.01
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Federico Pier
Full Time Employees
2
Sector
Healthcare
Industry
Biotechnology
Address
1735 Buford Highway Cumming GA United States of America 30024
IPO Date
Feb 23, 1998
CIK
0001468639
Website
vicapsys.com
Similar Companies
ProMIS Neurosciences, Inc. (PMN)
Jiangsu Sihuan Bioengineering Co., Ltd (000518.SZ)
Chabiotech Co.,Ltd. (085660.KQ)
3B BlackBio Dx Ltd (3BBLACKBIO.BO)
Molecular Partners AG (MOLN)
Adynxx, Inc. (ADYX)
Business
Vicapsys Life Sciences, Inc. Vicapsys Life Sciences, Inc. (VICP) is a clinical-stage biotechnology company that develops and commercializes proprietary CXCL12-based therapies to create localized immune protection for cells, tissues, organs, and devices, targeting chronic inflammatory conditions without systemic immunosuppression. The company offers VICAPSYN, an alginate-encapsulated product line for transplantation therapies including stem-cell derived beta-islet cells to treat Type 1 diabetes by enabling long-term survival of transplanted allogeneic human islet cells in the peritoneal cavity; and ViBrin, a non-cellular CXCL12 formulation complexed into bioabsorbable polymers applied post-debridement to accelerate healing of diabetic foot ulcers through inflammation inhibition, stem cell recruitment, and angiogenesis, or to prevent post-surgical peritoneal adhesions by blocking fibrosis and immune responses at incision sites. Founded in 1997 and headquartered in Suwanee, Georgia, Vicapsys Life Sciences operates primarily in the United States with a global development focus, leveraging technology exclusively licensed from Massachusetts General Hospital in 2013 and supported by eight patent families covering cellular and non-cellular applications; the company employs a small team of two and trades on OTC Markets. Recent advancements include ongoing non-human primate studies demonstrating six-month functionality of CXCL12-protected stem cell-derived beta cells in healthy models with diabetic primate trials in progress, alongside preclinical validation of ViBrin for wound healing and adhesion prevention in validated animal models. In 2022, the company appointed three new board members—Richard Rosenblum, Dr. Colleen Delaney, and Charles Farrahar—and named Federico Pier as permanent CEO, following platform milestones like reduced transplant rejection in primate studies initiated in 2016-2017; no major acquisitions, funding rounds, or partnerships have been announced in the last two years.